FMP
OncoCyte Corporation
OCX
NASDAQ
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
2.08 USD
-0.04 (-1.92%)
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
-
1.22M
7.73M
958k
1.5M
1.76M
2.07M
2.43M
2.85M
3.34M
-
-
535.44
-87.6
56.89
17.32
17.32
17.32
17.32
-21.89M
-30.54M
-48.46M
-13.31M
-23.12M
-1.06M
-1.24M
-1.46M
-1.71M
-2M
100
-2.51k
-627.11
-1.39k
-1.54k
-60
-60
-60
-60
-22.24M
-30.93M
-52.66M
-18.54M
-24.8M
-1.06M
-1.24M
-1.46M
-1.71M
-2M
100
-2.54k
-681.53
-1.93k
-1.65k
-60
-60
-60
-60
344k
394k
4.21M
5.22M
1.68M
1.36M
1.6M
1.88M
2.2M
2.58M
100
32.4
54.42
544.89
111.78
77.36
77.36
77.36
77.36
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)